Abstract
Dynamic contrast-enhanced (DCE) MR imaging is used increasingly often to evaluate tumor angiogenesis and the efficacy of antiangiogenic drugs. In clinical practice DCE-MR imaging applications are largely centered on lesion detection, characterization, and localization. In research, DCE-MR imaging helps inform decision making in early-phase clinical trials by showing efficacy and by selecting dose and schedule. However, the role of these techniques in patient selection is uncertain. Future research is required to optimize existing DCE-MR imaging methods and to fully validate these biomarkers for wider use in patient care and in drug development.
Original language | English |
---|---|
Pages (from-to) | 45-56 |
Number of pages | 12 |
Journal | Magnetic Resonance Imaging Clinics of North America |
Volume | 24 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Feb 2016 |
Keywords
- Angiogenesis
- Biomarker
- Clinical trials
- DCE-MR imaging
- Diagnosis
- Quantitative imaging